The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | State-of-the-art treatment regimens for LR-MDS
Valeria Santini, MD, University of Florence, Florence, Italy, gives an overview of the treatment landscape for lower-risk myelodysplastic syndromes (LR-MDS). Dr Santini talks on the role of imetelstat and luspatercept for patients with LR-MDS who are relapsed/refractory to erythropoiesis-stimulating agents (ESAs). In particular, Dr Santini comments on the potential use of luspatercept in patients with MDS who do not have ring sideroblasts, and highlights the efficacy of imetelstat in patients with SF3B1. Dr Santini also highlights evidence for the use of eltrombopag in patients with MDS and thrombocytopenia, and studies of lower doses of hypomethylating agents (HMAs). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
